Interesting RedHill came out with a similar PR tod
Post# of 1418
(Total Views: 336)
Posted On: 04/11/2022 11:29:32 AM
Interesting RedHill came out with a similar PR today exactly a week later. “Imitation is the sincerest form of flattery that mediocrity can pay to greatness.”
Although I'm not 100% sure they tested it against BA.1 and BA.2 strains of the Omicron as that is not as clearly stated as it is in the Todos PR.
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants - April 04, 2022 9:11am EDT
https://investor.todosmedical.com/news-events...ibition-in
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro - Apr 11, 2022, 09:00 ET
https://www.redhillbio.com/news/news-details/...fault.aspx
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
February 7, 2022
Small study, but looks like 3 people died on Opaganib.
"The prespecified mortality analysis, undertaken for all patients from the Phase 2/3 study who were receiving remdesivir and corticosteroids at baseline, demonstrated a significant 70.2% mortality benefit for opaganib-treated patients, with a mortality rate of 6.98% (n=3/43) for the opaganib arm + SoC versus 23.4% (n=11/47) for placebo + SoC by Day 42 (p-value=0.034)."
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 i n Non-Hospitalized COVID-19 - March 1, 2022
https://www.redhillbio.com/news/news-details/...fault.aspx
This study seemed kind of small for Non-Hospitalized but kept everyone out of the hospital although not many were hospitalized in the control group either.
"100% reduction in hospitalization due to COVID-19 with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm"
"87.8% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only one patient in the RHB-107 treated group 2.4%, (1/41) versus 20% (4/20) of patients in the placebo-controlled arm"
https://www.redhillbio.com/news/news-details/...fault.aspx
Although I'm not 100% sure they tested it against BA.1 and BA.2 strains of the Omicron as that is not as clearly stated as it is in the Todos PR.
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants - April 04, 2022 9:11am EDT
https://investor.todosmedical.com/news-events...ibition-in
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro - Apr 11, 2022, 09:00 ET
https://www.redhillbio.com/news/news-details/...fault.aspx
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
February 7, 2022
Small study, but looks like 3 people died on Opaganib.
"The prespecified mortality analysis, undertaken for all patients from the Phase 2/3 study who were receiving remdesivir and corticosteroids at baseline, demonstrated a significant 70.2% mortality benefit for opaganib-treated patients, with a mortality rate of 6.98% (n=3/43) for the opaganib arm + SoC versus 23.4% (n=11/47) for placebo + SoC by Day 42 (p-value=0.034)."
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 i n Non-Hospitalized COVID-19 - March 1, 2022
https://www.redhillbio.com/news/news-details/...fault.aspx
This study seemed kind of small for Non-Hospitalized but kept everyone out of the hospital although not many were hospitalized in the control group either.
"100% reduction in hospitalization due to COVID-19 with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm"
"87.8% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only one patient in the RHB-107 treated group 2.4%, (1/41) versus 20% (4/20) of patients in the placebo-controlled arm"
https://www.redhillbio.com/news/news-details/...fault.aspx
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼